Table 2 List of RSA drugs in South Korea

Activation ongoing

 Erbitux

cetuximab

refund

5-Mar-2014

re-evaluation for RSA (1-Jul-2018)

 Xtandi

enzalutamide

refund

1-Nov-2014

re-evaluation for RSA (13-Feb-2019)

 Soliris

eculizumab

refund

1-Oct-2015

refund pilot program (1-Oct-2012),

Essential drug

 Caprelsa

vandetanib

expenditure cap

1-Nov-2015

Under EEE

 Naglazyme

galsulfase

refund

1-Mar-2016

refund pilot program (1-Oct-2012),

Essential drug

 Stivarga

regorafenib

refund

1-Jun-2016

 Vimizim

elosulfase alfa

expenditure cap

1-Jun-2016

Under EEE

 Pomalyst

pomalidomide

refund

1-Jan-2017

 Defitelio

defibrotide

expenditure cap

1-Jun-2017

Under EEE

 Perjeta

pertuzumab

time cap

per patient

1-Jun-2017

 Zelboraf

vemurafenib

expenditure cap

1-Jul-2017

Under EEE

 Kadcyla

trastuzumab emtansine

utilization cap

3-Aug-2017

 Opdivo

nivolumab

refund +

expenditure cap

21-Aug-2017

 Keytruda

pembrolizumab

refund +

expenditure cap

21-Aug-2017

 Rafinlar

dabrafenib

expenditure cap

1-Sep-2017

Under EEE

 Lynparza

olaparib

expenditure cap

1-Oct-2017

Under EEE

 Meqsel

trametinib

expenditure cap

1-Nov-2017

Under EEE

 Ibrance

palbociclib

refund

6-Nov-2017

 Tagrisso

osimertinib

discounted

treatment initiation

5-Dec-2017

 Tecentriq

atezolizumab

expenditure cap

12-Jan-2018

Under EEE

 Sylvant

siltuximab

expenditure cap

1-Feb-2018

Under EEE

 Kyprolis

carfilzomib

refund

5-Feb-2018

 Iclusig

ponatinib

expenditure cap

1-Apr-2018

Under EEE

 Imbruvica

ibrutinib

expenditure cap

1-Apr-2018

Under EEE

 Cyramza

ramucirumab

refund

1-May-2018

 Blincyto

blinatumomab

expenditure cap

1-Jul-2018

Under EEE

 Vyndaqel

tafamidis

expenditure cap

1-Oct-2018

Under EEE

 Cabometyx

cabozantinib

refund +

expenditure cap

1-Feb-2019

 Praxbind

idarucizumab

expenditure cap

1-Feb-2019

Under EEE

 Darzalex

daratumumab

refund +

expenditure cap

8-Apr-2019

 Spinraza

nusinersen

refund +

expenditure cap

8-Apr-2019

Limited activation

 Olita

olmutinib

expenditure cap

15-Nov-2017

Under EEE

 Lartruvo

olaratumab

expenditure cap

1-Dec-2018

Under EEE

Expired activation

 Evoltra

clofarabine

CED

11-Dec-2013

(1-Dec-2018)

the first RSA drug,

conventional reimbursement after re-evaluation

 Revlimid

lenalidomide

refund

5-Mar-2014

(1-Dec-2017)

conventional reimbursement due to generic

 Xalkori

crizotinib

refund

1-May-2015

(1-May-2019)

conventional reimbursement due to alternative drugs after re-evaluation

 Pirespa

pirfenidone

refund

3-Oct-2015

(1-Nov-2017)

conventional reimbursement due to generic

 Diterin

sapropterin

expenditure cap

1-Nov-2017

(8-May-2019)

Under EEE,

conventional reimbursement due to generic

 Alecensa

alectinib

hydrochloride

expenditure cap

1-Oct-2017

(1-Dec-2018)

Under EEE,

conventional reimbursement due to alternative drugs after expansion of the indication